February 9, 2021
HEALTHY RETURNS: PROGNOSIS FOR RECOVERY
On February 9, CNBC’s Healthy Returns spotlight will update attendees with up-to-the minute information on the rollout of Covid-19 vaccines, for investors, policy makers and business leaders. As new vaccines continue to be approved, we’ll check in on the largest and most complicated mass vaccination program in history, how government and the private sector are working together, bringing an end to this pandemic. Plus – treating the mental health crisis brought about by Covid-19, the long lasting impact on people, business and the economy.
Featuring keynote and panel interviews, plus concurrent sessions, this event stands squarely at the intersection of the pandemic, economics and business to give critical information to move forward.
WHO SHOULD ATTEND: Health care investors, VCs, C-Suite executives from the biotech, pharma, health care and life sciences industries, health care IT BDMs.
Watch our 2020 Event Highlights
Visit cnbc.com/healthy-returns to find in-depth coverage from the CNBC team about health care innovation.
Subscribe to our Healthy Returns newsletter for exclusive insights on the biggest health care news from our reporters, delivered straight to your inbox every Friday.
Alex Gorsky is Chairman of the Board and Chief Executive Officer of Johnson & Johnson and Chairman of the Executive Committee, the Company’s senior leadership team. Alex is the seventh person to serve as Chairman and CEO of Johnson & Johnson since it became a publicly traded company in 1944.
Alex began his Johnson & Johnson career as a sales representative with Janssen Pharmaceutica in 1988. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing and management including assignments in the U.S., Europe, Africa and the Middle East. He progressed through many management posts at J&J, culminating in being named Chief Executive Officer on April 26, 2012 and Chairman of the Board on December 28, 2012.
Under Alex Gorsky’s leadership, Johnson & Johnson continues in its 132nd year to be one of the world’s exceptional corporations. The company was given the #1 ranking on Barron’s Magazine’s 2016 list of the “World’s Most Admired Companies,” and is currently the number one Pharmaceutical company on Fortune Magazine’s list of the “World’s Most Respected Companies.
A longtime advocate of Diversity Inclusion and Veteran’s issues, Alex has been named one of the “100 Most Inspiring Leaders” by Pharma Voice. Most recently, in December of 2017, Alex received the Ripple of Hope Award from the Robert F. Kennedy Human Rights Foundation. And for the past three years, Alex has been on the list of the Highest Rated CEOs on The Glassdoor Employees’ Choice Awards. He has also received the Jackie Robinson Award, Appeal of Conscience Award, the Joseph Wharton Leadership Award and the CADCA Humanitarian of the Year Award.
Alex is a member of the Board of Directors of IBM, the Wharton School of Business Board of Overseers and the Board of Directors of the Business Roundtable.
Alex holds a Bachelor of Science degree from the U.S. Military Academy at West Point, N.Y., and spent six years in the U.S. Army, finishing his military career with the rank of Captain. Alex earned a Master of Business Administration degree from The Wharton School of the University of Pennsylvania in 1996.
Rick Gates is senior vice president of pharmacy and healthcare at Walgreens, based in Deerfield Ill. He is responsible for commercial development and sales, contracting, pharma development, pharmacy supply chain, and clinical programs and alliances.
Before then he was group vice president of pharmacy where he led the strategic development, alignment and delivery of pharmacy-led health and wellness programs. He has served in roles of increasing responsibility since joining Walgreens in 1995 after graduation from pharmacy school including leading Walgreens Western Pharmacy Operations and responsible for integrating Duane Reade stores into the Walgreens network.
Rick serves as a board member with the National Association of Chain Drug Stores (NACDS) Foundation, University of Iowa College of Pharmacy Leadership Board, AllianceRx and Pharmacy Quality Alliance (PQA).
Rick received a B.S. in pharmacy from the University of Iowa in Iowa City. He is an active member of the American Pharmacist Association, NCPDP, NASP and the University of Iowa Alumni Association.
Anita Jenkins is the Chief Executive Officer at Howard University Hospital in Washington DC. As a key part of Howard’s partnership with Adventist Healthcare, Jenkins is leading the transformational three-year management services agreement with Adventist as Howard University Hospital continues to provide care to its surrounding community in a culturally focused environment. She will also be guiding Howard University Hospital through its new replacement hospital project with a focus on improving patient safety, patient quality, and patient outcomes.
In her over 20 years of healthcare experience and leadership, Jenkins developed expertise in hospital operations, healthcare management, and strategic planning. Prior to her role at Howard University Hospital, Anita Jenkins was president of Sycamore Medical Center near Dayton, Ohio. While there, she was responsible for daily operations of all clinical inpatient and outpatient services including nursing, rehabilitation, and patient relations.
Anita Jenkins’ approach to the business side of healthcare is informed by her days as a respiratory therapist at the University of Pittsburgh Medical Center where Jenkins gained first-hand experience in caring for patients with compassion. This background translates into her focus as Howard University Hospitals new CEO, working directly with staff and the DC community. Since assuming her role at Howard University Hospital at the onset of the COVID-19 pandemic, Jenkins has focused her efforts on understanding DC’s changing landscape, and how to best serve the DC area community.
Marc Rogers is VP of Cybersecurity at Okta. With a career that spans more than twenty years, he has been hacking since the 80’s and is now a white-hat hacker renowned for hacking things like Apple's TouchID and the Tesla Model S. Prior to Okta, Mr. Rogers served as the Head of Security for Cloudflare and spent a decade managing security for the UK operator, Vodafone. He's been a CISO in South Korea and has also co-founded a disruptive Bay Area startup. In his role as technical advisor on “Mr. Robot,” he helped create hacks for the show. He's also an organizer and the Head of Security for the world’s largest hacking conference: DEF CON. Most recently Mr Rogers helped found the CTI League, a multinational cybersecurity initiative combining industry professionals, government agencies and law enforcement from 80 different countries.
12:30pmEST
12:45pmEST
Share your thoughts, shape the conversation
Healthy Returns Spotlight will kick off with a CNBC moderated attendee-driven chat. Topics include; vaccine distribution, how the new administration should handle this phase of the pandemic, what’s ahead for the health care industry, and more. We invite you to share your thoughts with peers in your industry and weigh in on critical issues facing health care now and in the future.
Moderator: Berkeley Lovelace, Health Care Reporter, CNBC
1:00pmEST
Retail pharmacies will play a vital role inoculating Americans from every corner of the country, amidst massive logistical and staffing challenges. We’ll get a behind-the-scenes look at the obstacles they face, and their role to help end the pandemic.
Rick Gates, SVP, Pharmacy & Healthcare, Walgreens
Interviewer: Meg Tirrell, Senior Health & Science Reporter, CNBC
Watch the full interview
1:15pmEST
When Covid hit, hospitals were without a playbook on how to navigate the sudden onslaught of sick patients, shutdown of outpatient services, operational challenges, lost revenue, and more. One CEO will join us to talk about lessons learned, and strategies for the future.
Anita Jenkins, CEO, Howard University Hospital
Interviewer: Bertha Coombs, Reporter, CNBC
Watch the full interview
1:25pmEST
As the Covid-19 vaccine rollout continues, cybersecurity experts are sounding the alarm over growing threats of tampering and theft by cybercriminals targeting the supply chain. We’ll discuss who’s most at risk, and what can be done to stop potential hacks before they happen.
Marc Rogers, former hacker/Executive Director of Cybersecurity, Okta
Interviewer: Kate Rooney, Technology Reporter, CNBC
Watch the full interview
1:40pmEST
Data Analytics, Vaccine Passports & the Path to a New Normal
Sponsored and programmed by Change Healthcare
In this session, we will explore how securely leveraging key social determinants of health (SDoH) data can better inform provider approaches for individual patients, and accelerate a consumer-friendly approach to normalcy during and after the Covid pandemic through the implementation of vaccine passports.
Tim Suther, SVP and General Manager, Data Solutions, Change Healthcare
Kris Joshi, EVP, Network Solutions, Change Healthcare
Moderator: Shibani Joshi, Technology Journalist
Watch the full interview
Mental Health: An Out-of-the-Box Approach
With the US in the midst of what’s being called the worst mental health crisis in decades, one expert is taking an unconventional approach to reaching individuals who need help, using the unlikeliest of tech platforms.
Alok Kanojia, MD, Psychiatrist; President, Healthy Gamer
Interviewer: Sharon Epperson, Senior Personal Finance Correspondent, CNBC
Watch the full interview
2:00pmEST
Johnson & Johnson’s Covid-19 vaccine is being hailed as a potential “game changer,” because of its single dose. We’ll receive an update from the company’s CEO on the status of FDA approval, along with an exclusive look into the process of developing a life-saving vaccine.
Alex Gorsky, CEO, Johnson & Johnson
Interviewer: Meg Tirrell, Senior Health & Science Reporter, CNBC
Watch the full interview
2:30pmEST
REGISTER FOR OUR ANNUAL SUMMIT – May 11, 2021.
Subscribe to our Healthy Returns newsletter for exclusive insights on the biggest health care news from our reporters, delivered straight to your inbox every Friday.
You can also visit cnbc.com/healthy-returns for relevant content from the event and all-things health care investing and innovation.
Change Healthcare is a leading independent healthcare technology company, focused on insights, innovation and accelerating the transformation of the healthcare system through the power of the Change Healthcare platform. We provide data and analytics-driven solutions to improve clinical, financial, administrative, and patient engagement outcomes in the U.S. healthcare system.
Our platform and comprehensive suite of software, analytics, technology enabled services and network solutions drive improved results in the complex workflows of healthcare system payers and providers by enhancing clinical decision making, simplifying billing, collection and payment processes, and enabling a better patient experience.
Our Intelligent Healthcare Network is one of the largest clinical and financial healthcare networks in the U.S., facilitating over 15 billion transactions and approximately $1.5 trillion in adjudicated claims, or more than one-third of all U.S. healthcare expenditures. Our customer base includes approximately 2,400 government and commercial payer connections, 1,000,000 physicians, 125,000 dentists, 39,000 pharmacies, 6,000 hospitals and 700 laboratories.
Giovanni Caforio, M.D., is Chairman of the Board and chief executive officer of Bristol Myers Squibb. Under Giovanni’s leadership, BMS is delivering innovative medicines to treat patients with cancer, auto-immune diseases and cardiovascular disease, and is advancing one of the most diverse and promising pipelines in the industry. Giovanni leads a diverse global workforce dedicated to the company’s mission of discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.
Giovanni was appointed CEO in 2015 and elected as Chairman of the Board of Directors in 2017. As part of Bristol Myers Squibb’s strategy to combine the agility of a biotech with the reach and scale of an established pharma company, Giovanni led the company’s acquisition of Celgene in 2019. Today the company is a leading biopharma company focused on transforming patients’ lives through science. He has developed a strong patient-focused culture, with teams who are passionate about the work they do to help address some of the most challenging diseases of our time. He has led BMS’ drive to promote an inclusive culture where employees are encouraged to challenge the status quo and bring forward solutions.
Giovanni is an active champion for a policy environment that values healthcare innovation and supports patient access to medicines. Reflecting his advocacy, in 2015 he joined the Board of Directors for the Pharmaceutical Research and Manufacturers of America, known as PhRMA, and in 2019 was named Chairman.
Prior to becoming CEO, Giovanni served as chief operating officer with responsibility for leading a fully integrated worldwide commercial organization and the companywide functions of Enterprise Services and Global Manufacturing & Supply. This was preceded by appointment as the company’s chief commercial officer.
Born and educated in Italy, Giovanni received his medical doctorate from the University of Rome. He started his career with Abbott Laboratories before joining Bristol-Myers Squibb in 2000 as vice president and general manager, Italy, in the Worldwide Medicines Group. Giovanni advanced through a series of regional European management positions and, in 2004, became senior vice president, European Marketing and Brand Commercialization. In 2007, he relocated to the U.S. as senior vice president, U.S. Oncology. He was named senior vice president, Global Commercialization, Oncology and Immunology in 2010, then became president of the company’s U.S. organization in 2011.
Stéphane Bancel has served as Moderna's Chief Executive Officer since October 2011 and as a member of Moderna’s board of directors since March 2011. Before joining the company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux.
Mr. Bancel currently serves on the board of directors of Indigo. He is currently a Venture Partner at Flagship Pioneering. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School.
Martine Rothblatt is Chairman & CEO of United Therapeutics, a biotechnology company she started to save the life of one of her daughters. The company offers FDA approved medicines for pulmonary hypertension and neuroblastoma and is working on manufacturing an unlimited supply of transplantable organs.
Dr. Rothblatt previously created and led Sirius XM as its Chairman & CEO, and launched other satellite systems for navigation and international television broadcasting. In the field of aviation her Sirius XM satellite system enhances safety with real-time digital weather information to pilots in flight nationwide. She also designed the world’s first electric helicopter, which in 2018 set Guinness world records for distance and flight duration.
In the legal arena, Dr. Rothblatt led efforts to create transgender health law standards, and to protect privacy and autonomy rights in genetic information via an international treaty. She has Bachelor’s (Communications Studies, Summa Cum Laude), JD and MBA degrees from UCLA, and a Ph.D. in Medical Ethics from the Royal London School of Medicine & Dentistry. Her patented inventions cover aspects of satellite radio, prostacyclin biochemistry and cognitive software. Dr. Rothblatt’s recent books are on xenotransplantation (Your Life or Mine), non-binary gender identity (Transgender to Transhuman) and cyberethics (Virtually Human).
Alex Gorsky is Chairman of the Board and Chief Executive Officer of Johnson & Johnson and Chairman of the Executive Committee, the Company’s senior leadership team. Alex is the seventh person to serve as Chairman and CEO of Johnson & Johnson since it became a publicly traded company in 1944.
Alex began his Johnson & Johnson career as a sales representative with Janssen Pharmaceutica in 1988. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing and management including assignments in the U.S., Europe, Africa and the Middle East. He progressed through many management posts at J&J, culminating in being named Chief Executive Officer on April 26, 2012 and Chairman of the Board on December 28, 2012.
Under Alex Gorsky’s leadership, Johnson & Johnson continues in its 132nd year to be one of the world’s exceptional corporations. The company was given the #1 ranking on Barron’s Magazine’s 2016 list of the “World’s Most Admired Companies,” and is currently the number one Pharmaceutical company on Fortune Magazine’s list of the “World’s Most Respected Companies.
A longtime advocate of Diversity Inclusion and Veteran’s issues, Alex has been named one of the “100 Most Inspiring Leaders” by Pharma Voice. Most recently, in December of 2017, Alex received the Ripple of Hope Award from the Robert F. Kennedy Human Rights Foundation. And for the past three years, Alex has been on the list of the Highest Rated CEOs on The Glassdoor Employees’ Choice Awards. He has also received the Jackie Robinson Award, Appeal of Conscience Award, the Joseph Wharton Leadership Award and the CADCA Humanitarian of the Year Award.
Alex is a member of the Board of Directors of IBM, the Wharton School of Business Board of Overseers and the Board of Directors of the Business Roundtable.
Alex holds a Bachelor of Science degree from the U.S. Military Academy at West Point, N.Y., and spent six years in the U.S. Army, finishing his military career with the rank of Captain. Alex earned a Master of Business Administration degree from The Wharton School of the University of Pennsylvania in 1996.
